Ȳ¹Ý º¯¼º °Ë»ç ¹× Ä¡·á(Macular Degeneration Testing and Therapeutics) ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È CAGR 3.42%·Î È®´ëµÇ¾î 2022³â 118¾ï 3,200¸¸ ´Þ·¯¿¡¼ 2029³â¿¡´Â 149¾ï 5,900¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Ȳ¹Ýº¯¼º °Ë»ç ¹× Ä¡·á´Â ¼±¸íÇÑ Á᫐ ½Ã·ÂÀ» ´ã´çÇÏ´Â ¸Á¸·ÀÇ Á߽ɺÎÀΠȲ¹Ý¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀϹÝÀûÀÎ ¾È°ú Áúȯ¿¡ ´ëÇÑ Áø´Ü ¹æ¹ý ¹× Ä¡·á¹ýÀÔ´Ï´Ù. Ȳ¹Ýº¯¼º¿¡´Â °Ç¼º(À§Ã༺)°ú ½À¼º(½Å»ýÇ÷°ü¼º ¶Ç´Â »ïÃ⼺)ÀÇ µÎ °¡Áö ÁÖ¿ä À¯ÇüÀÌ ÀÖ½À´Ï´Ù. °Ë»ç¿¡´Â ½Ã·Â °Ë»ç, ¾È±¸ È®Àå °Ë»ç, Ç÷ç¿À·¹¼¼ÀÎ Ç÷°ü Á¶¿µ¼ú, ºû°£¼·´ÜÃþÃÔ¿µ(OCT), À¯ÀüÀÚ °Ë»ç°¡ Æ÷ÇԵ˴ϴÙ.
Ȳ¹Ý º¯¼º °Ë»ç ¹× Ä¡·á ½ÃÀå¿¡´Â ŽÁö, ¸ð´ÏÅ͸µ, È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇϱâ À§ÇÑ Áø´Ü µµ±¸, ÀǾàǰ, º¸ÃæÁ¦ ¹× ÀÇ·á±â±â°¡ Æ÷ÇԵ˴ϴÙ. Áø´Ü µµ±¸¿¡´Â OCT ÀåÄ¡, ¾ÈÀú Ä«¸Þ¶ó, Ç÷ç¿À·¹¼¼ÀÎ Ç÷°ü Á¶¿µ ½Ã½ºÅÛ, Ç×-VEGF ¾à¹°, º¸ÃæÁ¦, ¾È±¸ ÀÓÇöõÆ®, ¾à½Ã º¸Á¶ ±â±¸, À¯ÀüÀÚ °Ë»ç ¼ºñ½º µîÀÌ Æ÷ÇԵ˴ϴÙ. °í·ÉÈ, ¿µ»ó Áø´Ü ±â¼úÀÇ Áøº¸, ½Å±Ô Ä¡·á Á¢±Ù¹ýÀÇ Áö¼ÓÀûÀÎ ¿¬±¸°¡ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
¿¬±¸°³¹ß ³ë·Â È®´ë¿Í ÀÓ»ó½ÃÇè Áõ°¡°¡ ¾÷°è ¼ºÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß Ȱµ¿Àº Ȳ¹Ýº¯¼º°Ë»ç ¹× Ä¡·á¾÷°è¸¦ µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â µ¶Ã¢ÀûÀÎ Ä¡·á Á¢±Ù¹ý È®´ë, °íǰÁú À¯ÀüÀÚ Ä¡·á, Áٱ⠼¼Æ÷ Ä¡·á, º´¿ë Ä¡·á µîÀÌ Æ÷ÇԵ˴ϴÙ. ¹ß°ßÀÇ Ä¡·á ÁøÀü°ú ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Áøº¸´Â Á¶±â ¹ß°ß°ú °³ÀÎÈ Ä¡·á¿¡ ÈûÀ» ÁÝ´Ï´Ù. »õ·Î¿î Á¦Çü°ú ¼¹æÇü ÀÓÇöõÆ®¸¦ Æ÷ÇÔÇÑ °í±Þ ¾à¹° Àü´Þ ÇÁ·¹ÀÓ ¿öÅ©°¡ ±¸ÃàµÇ°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½Å¾à°ú Ä¡·á¹ýÀÇ »ó¾÷ȸ¦ º¸ÀåÇϱâ À§ÇÑ ÀÓ»ó½ÃÇèÀÌ ½ÃÀ۵ǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ±ÔÁ¦±â°üÀÇ ½ÂÀΰú Ȳ¹Ýº¯¼º ½Å¾àÀÇ »ó¾÷È·Î À̾îÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 11¿ù, À¯ÀüÀÚ Ä¡·áÁ¦¿¡ Æ¯ÈµÈ ÀÓ»ó ´Ü°èÀÇ »ý¸í °øÇÐ ±â¾÷ÀÎ 4D Molecular Ceraputics´Â ½À¼º ¿¬·É Ȳ¹Ýº¯¼º(AMD)¿¡ ´ëÇÑ À¯¸®Ã¼³» 4D-150ÀÇ I/II »óÀÓ»ó½ÃÇèÀÇ Áß°£ ¹ß°ßÀ» º¸°íÇß½À´Ï´Ù.
Ȳ¹Ýº¯¼º°Ë»ç ¹× Ä¡·á¾÷°è´Â ƯÈ÷ °³¹ßµµ»óÀÇ ´ëÁß °¡¿îµ¥ ½Ã·ÂÀå¾ÖÀÇ ±âº»ÀûÀÎ ¿øÀÎÀÎ ¿¬·ÉȲ¹Ýº¯¼º(AMD)ÀÇ À¯º´·ü Áõ°¡·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áøº¸ÀÇ ¿äÀο¡´Â ¼¼°è Àα¸ÀÇ °í·ÉÈ, ¿µ¾ç ½ÇÁ¶¸¦ ÀÏÀ¸Å°´Â ½Ä»ýȰÀÇ È¥¶õ, ºñ¸¸, Èí¿¬, À½ÁÖ µî »ýȰ ½À°ü, OCT µî ½ÇÁõÀûÀÎ ±â¼ú Áøº¸ÀÇ ¾àÁø, ´« °Ç°°ú ½ºÅ©¸®´× ÇÁ·Î±×·¥ÀÇ Á߿伺¿¡ °üÇÑ ÀÇ½Ä È®´ë µîÀÌ ÀÖ½À´Ï´Ù.
¸Á¸· Áúȯ Áõ°¡ Ãß¼¼´Â ¾÷°èÀÇ ¹ßÀü¿¡ ±â¿©ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, British Journal of Ophthalmology¿¡ ÀÇÇÑ 2020³â 8¿ù ¼³¹®Á¶»ç´Â AMD°¡ À¯·´¿¡¼ ½Ã°¢ Àå¾Ö¿Í ½Ã°¢ »ó½ÇÀÇ ÁÖ¿ä ¿äÀÎÀ̶ó°í ¸»Çß½À´Ï´Ù. À¯·´¿¡¼´Â ¾à 6,700¸¸ ¸íÀÌ AMDÀÇ ¿µÇâÀ» ¹Þ°í ÀÖÀ¸¸ç, ¼¼°è ³ëÀÎ Àα¸°¡ È®´ëµÊ¿¡ µû¶ó 2050³â±îÁö 15%±îÁö Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Åë°è µ¥ÀÌÅÍ´Â ¸Á¸· ÁúȯÀÇ È¯ÀÚ ¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç ƯÈ÷ Ȳ¹Ý º¯¼º Ä¡·á¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í ÀÖÀ½À» ³ªÅ¸³À´Ï´Ù.
ºÏ¹Ì°¡ ½ÃÀå Á¡À¯À²À» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì ½ÃÀå ÁøÃâ ±â¾÷Àº ³ëÀÎ Àα¸ Áõ°¡¿Í ³ëÈ È²¹Ý º¯¼ºÀÇ ¿ìÀ§¼º µî ´Ù¾çÇÑ ¿ä¼Ò ¿Ü¿¡µµ ÁÖ¿ä ¾÷°è ±â¾÷ÀÇ ÁøÀÔ°ú ½ÃÀå ÁøÃâ±â¾÷°ú Çмú ¿¬±¸ ±â°üÀÇ Á¦ÈÞ¿¡ ÀÇÇÑ ¿¬±¸ °³¹ß Ȱµ¿ È®´ë °¡ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 8¿ù¿¡ Nature Medicine ÀâÁö¿¡ °ÔÀçµÈ Á¶»ç¿¡¼´Â AMD ȯÀÚ°¡ SARS-CoV-2¿¡ °¨¿°µÇ¸é ½É°¢ÇÑ ÇÕº´ÁõÀ» ÀÏÀ¸Å³ °¡´É¼ºÀÌ ³ô°í »ê¼Ò ÈíÀÔÀÌ ÇÊ¿äÇϰųª, »ý¸í¿¡ °ü·ÃµÇ±âµµ ÇÏ´Â °ÍÀÌ ¹àÇôÁ³½À´Ï´Ù.
Ȳ¹Ýº¯¼º°Ë»ç ¹× Ä¡·á¾÷°è È®´ë¿¡ ±â¿©Çϰí ÀÖ´Â °ÍÀº ÷´Ü ÀÇ·áüÁ¦, Çõ½ÅÀû ±â¼ú Á¶»ç, ÀÇ·áÅõÀÚ Áõ°¡, Á¤ºÎȰµ¿, ȯÀÚÀǽÄ, Çмú¿¬±¸ÀÔ´Ï´Ù. Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê, Á¤Ã¥, ÀÓ»ó½ÃÇèÀº AMD¸¦ Á¶±â¿¡ ¹ß°ßÇϰí ÅëÁ¦ÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ÀϹÝÀûÀ¸·Î ÀÌ·¯ÇÑ ¿ä¼Ò´Â ºÏ¹Ì¿¡¼ ÃֽŠġ·á¹ýÀÇ Áøº¸¿Í »ó¾÷È¿¡ ¾ÕÀ¸·Î ¸î ³âµ¿¾È ±â¿©ÇÒ °ÍÀÔ´Ï´Ù.
¹Ì±¹ Ȳ¹Ý º¯¼ºÁõ Àç´Ü(AMDF)Àº AMD ȯÀÚ¿Í ¾È°ú Àü¹®°¡ ¸ðµÎ¿¡°Ô ÀáÀçÀûÀÎ À§Çè¿¡ ´ëÇØ ÁÖÀǸ¦ ±â¿ïÀ̱â À§ÇØ ÀÌ µ¥ÀÌÅ͸¦ ¹ßÇ¥Çß½À´Ï´Ù. AMD´Â ¼¼°èÀûÀ¸·Î µ¹ÀÌų ¼ö ¾ø´Â ½Ã°¢ Àå¾Ö¿Í ½Ã·Â Àå¾ÖÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ¾î ¾÷°èÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. 2021³â 2¿ù ij³ª´Ù ¾È°úÀÇ Á¤º¸¿¡ µû¸£¸é, ½À¼º AMD´Â 65¼¼ ÀÌ»óÀÇ »ç¶÷µéÀÇ ½Ã·Â »ó½ÇÀÇ Áß¿äÇÑ ¿øÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ ÄÁÆÛ·±½º º¸µå ¿Àºê ij³ª´ÙÀÇ Á¤º¸¿¡ µû¸£¸é ½Ã·Â ÀúÇÏ Æò°¡ ºñ¿ëÀº 2007³â 158¾ï ´Þ·¯¿¡¼ 2032³â±îÁö 303¾ï ´Þ·¯·Î ±ÞÁõÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global macular degeneration testing and therapeutics market is anticipated to expand at a CAGR of 3.42% amid the projected period to reach US$14.959 billion by 2029, from US$11.832 billion in 2022.
Macular degeneration testing and therapeutics are diagnostic methods and treatment approaches for the common eye condition, which affects the macula, the central part of the retina responsible for sharp, central vision. There are two main types of macular degeneration: dry (atrophic) and wet (neovascular or exudative). Tests include visual acuity tests, dilated eye exams, fluorescein angiography, optical coherence tomography (OCT), and genetic testing.
The market for macular degeneration testing and therapeutics includes diagnostic tools, pharmaceuticals, supplements, and medical devices designed to detect, monitor, and provide effective treatment options. Diagnostic tools include OCT machines, fundus cameras, fluorescein angiography systems, anti-VEGF drugs, supplements, intraocular implants, low vision aids, and genetic testing services. The market is driven by an aging population, advances in diagnostic imaging technology, and ongoing research into novel therapeutic approaches.
Expanding R&D endeavors and a rise in clinical trials characterized critical drivers of industry growth. R&D practices are anticipated to boost the macular degeneration testing and therapeutics industry. This incorporates expanding inventive therapeutic approaches, quality gene treatments, stem cell treatments, and combination treatments. Progressions in discovery and advancements in biomarkers empower early detection and personalized treatment. Progressed medication delivery frameworks are being created, involving novel formulations and sustained-release implants.
Additionally, Clinical trials are being started to guarantee the commercialization of new medicines and therapies These endeavors are anticipated to lead to regulatory bodies endorsements and the commercialization of new medications for macular degeneration. For instance, in November 2022, 4D Molecular Therapeutics, Inc., a clinical-stage biotechnology company specializing in focused on genetic medications, reported interim clinical discoveries from the Phase I/II trial of intravitreal 4D-150 for wet age-related macular degeneration (AMD).
The macular degeneration testing and therapeutics industry is expanding due to the increasing prevalence of age-related macular degeneration (AMD), a basic cause of vision inability, particularly inside the developing masses. Factors contributing to this advancement incorporate the worldwide aging populace, lifestyle habits such as poor diet causing malnutrition, obese population, smoking, and drinking, strides in demonstrative technological advancements such as OCT, and extended awareness around the significance of eye wellbeing and screening programs.
The growing predominance of retinal disorders is contributing to industry development. For instance, research in August 2020 by the British Journal of Ophthalmology stated that AMD is the primary factor of visual incapacity and visual loss in Europe. Around 67 million individuals in Europe are influenced by AMD, and this figure is expected to increase significantly to 15% by 2050 due to the expanding elderly population globally. These statistical data emphasize the rising number of people affected by retinal diseases, which particularly interfaces with the extended request for macular degeneration treatment and in this way drives market extension.
The North American area is expected to dominate the market share.
Market expansion in North America is driven by different components, like the increasing senior population and the predominance of age-related macular degeneration, in conjunction with the participation of key industry players and expanded R&D activities with the partnership of market players and academic research institutes. For instance, research published in Nature Medicine in August 2020 revealed that individuals with AMD who contract SARS-CoV-2 confront a higher chance of serious complications, involving requiring supplemental oxygen or can be fatal too.
The country's progressed healthcare framework, investigations for innovative technology, rising healthcare investment, government activities, awareness among patients, and academic research contribute to the macular degeneration testing and therapeutics industry expansion. Government initiatives and policies as well as clinical trials can offer assistance to identify and control AMD at an early stage. Generally, these components contribute to the advancement and commercialization of modern treatments in North America in the years ahead.
The American Macular Degeneration Foundation (AMDF) dispersed this data to alert both AMD patients and eye care experts about the potential risks involved. AMD is a driving main cause of irreversible visual impairment and visual disability universally, contributing to industry growth. According to information from the Canadian Ophthalmological Society from February 2021, wet AMD positions among the essential causes of vision loss in people aged over 65. Moreover, information from the Conference Board of Canada expressed that the evaluated cost of vision loss is projected to surge up to $30.3 billion by 2032 from $15.8 billion in the year 2007.